Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Drugs
- Therapeutic
- Disease
- Pharmaceuticals
- Gastrointestinal
- Vaccine
- Cancer
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 202385
License Grant
The Licensee entered into an exclusive license with the Licensor, a health sciences center, covering the underlying rotavirus vaccine technology used to generate the specific antibodies for our product line extension (First DefenseÃ’ Tri-Shieldâ„¢) that is under development.
License Property
The Vaccine technology is used for the Rotavirus – a contagious virus that can cause gastroenteritis (inflammation of the stomach and intestines).
Field of Use
First DefenseÃ’ Tri-Shieldâ„¢ is a natural treatment for scours, which causes diarrhea and dehydration in dairy and beef calves.
IPSCIO Record ID: 57817
License Grant
On May 2, 2010, the Licensee received a worldwide, exclusive and perpetual license to use patents and know how relating to BEKINDAâ„¢ from the previous Licensor, a U.S. company, who is now out of business. On March 7, 2014, the Company entered into a licensing agreement with a U.S. University to secure certain patent rights related to the drug candidate. The Company therefore terminated the agreement with the U.S. company and licensed the patents directly from the U.S. university, the original owner of the patents. Under the agreement, the Company agreed to pay the U.S. university certain future payments.
License Property
BEKINDAâ„¢ is a once-daily controlled release oral formulation of ondansetron, a leading member of the family of 5HT-3 serotonin receptor inhibitors for the treatment of gastroenteritis and gastritis.
Gastroenteritis, also known as infectious diarrhea, is inflammation of the gastrointestinal tract—the stomach and small intestine.
Gastritis is inflammation of the lining of the stomach.
Field of Use
The biopharmaceutical company is focused on the development and acquisition of late clinical-stage, proprietary, orally-administered drugs for the treatment of inflammatory and gastrointestinal diseases and cancer.
1)
Gastroenteritis and gastritis – 24 mg strength
2)
Irritable Bowel Syndrome with Diarrhea (IBS-D) – 12 mg strength
3)
Prevention of chemotherapy and radiotherapy induced nausea and vomiting (oncology support) – 24 mg strength
IPSCIO Record ID: 1296
License Grant
The Company licensed rights to the use of MTCH-24(tm) against three viruses, the aids virus (hiv), Epstein-Barr virus and cytomegalovirus to a party for an ownership share.
License Property
MTCH-24 is an anti-microbial agent effective against a wide range of other enveloped viruses such as influenza, Epstein-Barr virus (EBV), respiratory syncytial virus (RSV, a virus which affects the respiratory system), pseudorabies (a specific virus in the rabies family), rhino tracheitis (an infection of the lungs and throat), and cytomegalovirus (CMV). It is also believed to be effective against rotavirus, a non-enveloped virus that is a major cause of diarrhea and inflammation of the intestinal tract in infants and in certain animals. MTCH-24 (TM) has been shown to be effective in inhibiting and preventing the growth of Aspergillus on wheat and corn.
IPSCIO Record ID: 26030
License Grant
The Licensee is obligated to maintain a License with the Licensor with respect to the Glaxo Agreement.
In 1997, the Licensee entered into an Agreement with Glaxo to collaborate on the development and commercialization of the Licensee's oral rotavirus strain and Glaxo assumed responsibility for all subsequent clinical trials and all other development activities.
License Property
No additional milestone payments are due from Glaxo under the Agreement.
Field of Use
The Licensee Licensed-in the rotavirus strain that was used to develop Glaxo's Rotarix rotavirus vaccine and owes a License fee to the Licensor on net royalties received from Glaxo.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
